Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (9855)	11/30/1999 8:15:00 PM
From: Mohan Marette	Read Replies (1) \| Respond to of 12475

Glenmark Pharma IPO at Rs200 per share glenmarkindia.com 30-11-1999 16:46:51 Formulations manufacturer Glenmark Pharmaceuticals Ltd is launching an initial public offering (IPO) of equity shares at a price of Rs200 a share, company officials said today. The IPO is of 2.67mn shares, each of Rs10 face value at a premium of Rs190, aggregating Rs534mn, the officials told a news conference. The issue will open for subscription on December 10 and close on December 16. The Mumbai-based Glenmark conducts research, development, manufacture and marketing of drugs in the dermatology, paediatrics, gynecology and ENT (ear, nose throat) segments. Its major branded products include `Candid` cream in the dermatological segment and `Ascoril` expectorant. The firm has manufacturing facilities at Nashik in Maharashtra and in neighboring Goa state. It has its R&D center near Nashik. Glenn Saldanha, executive director of the company, said the IPO money would be used to set up a soft gelatin capsules manufacturing facility in Goa, an R&D center in Mumbai and for working capital expenditure. "We are working on diversifying into other segments while maintaining our leadership in dermatology," he said. The Mumbai R&D center will be ready by August 2000 and the Goa facility by end-2000, Saldanha said. The firm posted sales of Rs991.61mn, profit after tax of Rs127.74mn and earnings per share (EPS) of Rs25.81 in the year to March 31, 1999. Saldanha said the company expects to record sales of Rs1.37bn, net profit of Rs160mn and a post-issue fully-diluted EPS of Rs15.6 in the year to March 31, 2000. Source: Reuters